Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC
Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of intermittent use of darolutamide compared to long-term
use in combination with ADT and docetaxel in the treatment of mHSPC patients.
Phase:
Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University